Orem, UT

Andrea Johnson

Andes Clinical Research

Depressive Disorder

Major Depressive Disorder

Depression

GATE-251

Gate Neurosciences

condition

allSponsorName

Worldwide Clinical Trials

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are:

Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)?

What medical problems are observed in participants who take GATE-251?

Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.

GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Andes Clinical Research | Orem, UT

Site insights

Contact this site

Active trials

GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Trial sponsors